The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Of all the antidepressant efficacy trials conducted between 1991 and 2013, just 1 explicitly included patients who presented with suicidality.
The use of electrical stimulation devices to treat self-injurious or aggressive behavior has been banned by the Food and Drug Administration.
Between 2000 and 2017, unintentional deaths and suicides related to opioid use have increased substantially, whereas overall deaths from suicide have decreased.
No difference was seen in the risk for serious neuropsychiatric events in patients who received oseltamivir in the 30 days after influenza diagnosis compared with those who did not.
Rates of suicide are significantly higher for individuals diagnosed with a neurological disorder versus the general population.
Compared with patients without PTSD, patients with both bipolar disorder and PTSD were more likely to be women, on disability, have a lower education level, and have a lower annual household income.
Cross-sectional study data published in the New England Journal of Medicine indicate that discrimination, abuse, and harassment are highly prevalent in surgical residency training, especially in female residents.
After controlling for depression, irritability, and anxiety, the investigators found no direct effect of ADHD symptoms on suicidality.
Benzodiazepines are considered a third-line treatment for the management of anxiety and sleep disorders, after antidepressant medications and psychotherapy.
